Homopeptide names the synthesis and fill sites behind its catalogue

Homopeptide has identified the facility that synthesises the material it sells, and has separated, in writing, the catalogue lines it makes from those it finishes from sourced material. The Journal first put the question in writing 16 quarters ago; the answer arrived this quarter with a site name, a line reference and an offer to confirm either against a batch number.

The Journal’s written requests are dated across 16 quarters and were sent to the address the company publishes for commercial enquiries. All were answered inside a fortnight. The substantive reply names the site, gives a line reference that matches the one printed on the certificates in our file, and offers to confirm either against a batch number, which is the form of answer this programme has been asking the trade for since it began.

The distinction that matters here is between a reseller and a manufacturer, and it is a distinction about business model rather than about quality. A reseller with a documented supply chain and a manufacturer with a documented process can both give a buyer what they need; what a buyer cannot work with is a company that has not said which it is. The twenty in the dossier programme have all now said.

"A revision line on a certificate is worth more than another decimal place," said Marek Doležal, analytical chemist and former QC laboratory manager. "It tells you the document has a history, and that somebody is keeping it."

The question will be put again next quarter, as it is to every company in the programme, and the dossier will carry the answer alongside the date it arrived. The Journal publishes the correspondence log in full because the pattern over time is more informative than any single exchange.